Why Tesamorelin Is So Hard to Find

Tesamorelin is one of the harder compounds to find outside a pharmacy, and the reason is unusual: it isn’t just an approved drug, it’s regulated as a biologic.

What tesamorelin is

Tesamorelin is a synthetic analog of growth hormone–releasing hormone. It was first FDA-approved in 2010 as Egrifta, to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Newer versions followed: Egrifta SV in 2019 and Egrifta WR in 2025. All are prescription-only.

Why compounding is off the table

On March 23, 2020, a group of protein-based drugs that had been approved as ordinary drugs were moved to the biologics framework, and their approvals were “deemed to be” biologics licenses. Tesamorelin, a 44-amino-acid peptide, was on that list. Compounding pharmacies can’t use the usual compounding exemptions for biologics, so unlike many peptides there’s no lawful compounded version. The approved, prescription product is the route.

Price drives a gray market

The branded product is expensive, which creates demand for cheaper sources. That demand runs straight into the same enforcement pressure hitting the rest of the peptide market.

What regulators are actually targeting

The FDA’s recent warning letters to online peptide sellers, including a round on August 24, 2026, focused on websites marketing compounds for people: dosing charts, injection guides, weight-loss and before-and-after claims. That’s the line that matters. A research supplier sells to researchers, publishes a batch-specific Certificate of Analysis for every lot, and gives no dosing or human-use advice. Sellers that blur that line are the ones disappearing.

The payment squeeze

Payment access is the weak point for anyone selling peptides online. Card processors treat the whole category as high risk: Stripe lists peptides as a restricted business, and most processors simply refuse them. When drug makers and regulators turn up the pressure, processors and platforms are usually the first to act, and sellers that lose payment access tend to disappear within weeks.

That’s why so many listings vanish, change names or move to crypto-only and payment-app checkouts.

What it means if you’re looking

• Expect fewer, less stable sources. Sellers come and go, rename products or switch to payment methods with fewer protections.
• Counterfeit risk rises when supply shrinks. An independent, batch-specific Certificate of Analysis (identity by mass spectrometry, purity by HPLC) matters more than ever. A COA you can’t match to the batch you received isn’t proof of anything.
• Tesamorelin is a prescription medicine. Anyone interested in it as a treatment should talk to a licensed medical provider about the prescription options that exist today.

Sources

• FDA: List of approved drug applications for biological products deemed to be biologics licenses on March 23, 2020
• Theratechnologies: FDA approves the new tesamorelin formulation (Egrifta WR) (2025)
• FDA: Warning letters (public database)
• Stripe: Prohibited and restricted businesses

For the bigger picture on payments, see why payment processors avoid research peptides.

This article summarizes public reporting and regulatory actions. It is general information, not legal or medical advice, and nothing here is dosing or human-use guidance.